

---

## Communications

---

# Obtaining Family Psychiatric History in Family Practice and Pediatric Practice

Carrie Sylvester, MD, MPH, and Laura Kastner, PhD  
Seattle, Washington

A medical history usually includes a family history of disorders believed to be hereditary and a social history of circumstances that may affect patient care. Textbooks of medical interviewing suggest including mental disorders among those probably genetic disorders elicited in the family history. Genetic analysis of bipolar affective disorder (depressive illness) implies dominant transmission, whereas unipolar affective disorder (depression) seems to be pseudorecessive.<sup>1</sup> Schulsinger's study<sup>2</sup> of 10- to 20-year-old children of schizophrenic mothers indicates that their risk of schizophrenia is about eight times greater than that of matched control children. These children are also at increased risk for suicide or schizoid personality

disorder. The prevalence of anxiety disorder is about 5 percent in the general population and 49 percent in the children of anxiety neurotics.<sup>3</sup> Twin studies have demonstrated a high concordance for obsessive-compulsive disorder.<sup>4</sup>

Not only are mental disorders important for genetic reasons, but the mental health of family members is also a significant part of the social environment, especially for the child or adolescent patient. Two thirds of children aged 5 to 15 years whose parents had an affective disorder (depression or mania) have been found to be depressed.<sup>5</sup> Children of depressed parents have also been found to have significant anxiety, conduct problems, and impulsivity or hyperactivity.<sup>6</sup> It has been documented that primary care physicians failed to diagnose about 50 percent of patients with depression or other mental disorder when evaluating them in a medical setting.<sup>7</sup> It is possible that a large number of physicians who care for children do not obtain family history data, which would provide an index of risk for either mental disorder in children or a compromised family environment.

---


From the Division of Child Psychiatry, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington. Requests for reprints should be addressed to Dr. Carrie Sylvester, Department of Psychiatry, ZA-99, Harborview Medical Center, 325 9th Avenue, Seattle, WA 98104.

## Methods

An anonymous survey was conducted regarding the evaluation of children in medical practice. The survey was sent to 180 randomly selected members of the Washington chapter of the American Academy of Family Physicians, all 41 family practice residents in 2 Seattle programs, 200 randomly selected American members of the North Pacific Pediatric Society, and all 51 University of Washington pediatric house officers. The focus of this report is the following question about taking family history: "When taking a family medical/social history, do you routinely inquire about mental disorders, including depression, anxiety, suicide, and alcoholism?" The 12 answers of "usually" or "most of the time" were included as "yes." The two answers of "in adult patients only" were counted as "no."

## Results

Of the 472 questionnaires sent, 51.5 percent were returned. Family physicians constituted 41.7 percent of the respondents, and pediatricians, 58.3 percent of the respondents. Family history of mental disorder was reported to be obtained by 50.4 percent of the respondents and omitted by 49.6 percent of the respondents. Sex, population in practice location, and whether in residency or in practice yielded no significant differences. Family physicians obtained family histories significantly more often than pediatricians ( $\chi^2_1 = 19.43$ ,  $P < .001$ ). Whereas 67 percent of family physicians responded that they routinely inquire about mental disorders, 36 percent of pediatricians responded that they do so. When controlling for the specialty of the physician, age was a factor. The disparity between family physicians and pediatricians was greater for physicians aged 40 years or younger (Figure 1). There was no significant difference in the responses of family physicians and pediatricians aged 41 years and older. Responses did not differ by the number of years in practice. Physicians who provide office visits for psychosocial counseling were significantly more likely to inquire about family psychiatric history ( $\chi^2_1 = 8.80$ ,  $P < .005$ ). About 80 percent of both pediatricians and family physicians said that they provide some psychosocial counseling. There was no relation-



ship between taking a family history and providing counseling about specific medical issues including compliance with medical recommendations.

## Discussion

Questionnaires were completed anonymously to enhance the candor of responses. Also, embedding the family history question in a survey of other pediatric practices decreased the risk of significant response bias.

Nearly one half of the respondents reported that they fail to obtain a family history of common psychiatric disorders in routine medical examinations. Given the importance of family history, these results raised questions as to possible reasons for its omission from the interview. Nielsen and Williams<sup>7</sup> observed that details believed to be unimportant to medical evaluation are commonly excluded from the interview. Some respondents may

Continued on page 140

**ALDOMET® (Methyldopa/MSD)**

Tablets, containing 125, 250, or 500 mg methyldopa; Oral Suspension, containing 250 mg methyldopa per 5 ml and alcohol 1%.

**Contraindications:** Active hepatic disease, such as acute hepatitis and active cirrhosis; if previous methyldopa therapy has been associated with liver disorders (see Warnings); hypersensitivity.

**Warnings:** It is important to recognize that a positive Coombs test, hemolytic anemia, and liver disorders may occur with methyldopa therapy. The rare occurrences of hemolytic anemia or liver disorders could lead to potentially fatal complications unless properly recognized and managed. Read this section carefully to understand these reactions. With prolonged methyldopa therapy, 10% to 20% of patients develop a positive direct Coombs test, usually between 6 and 12 months of therapy. Lowest incidence is at daily dosage of 1 g or less. This on rare occasions may be associated with hemolytic anemia, which could lead to potentially fatal complications. One cannot predict which patients with a positive direct Coombs test may develop hemolytic anemia. Prior existence or development of a positive direct Coombs test is not in itself a contraindication to use of methyldopa. If a positive Coombs test develops during methyldopa therapy, determine whether hemolytic anemia exists and whether the positive Coombs test may be a problem. For example, in addition to a positive direct Coombs test there is less often a positive indirect Coombs test which may interfere with cross matching of blood. At the start of methyldopa therapy, it is desirable to do a blood count (hematocrit, hemoglobin, or red cell count) for a baseline or to establish whether there is anemia. Periodic blood counts should be done during therapy to detect hemolytic anemia. It may be useful to do a direct Coombs test before therapy and at 6 and 12 months after the start of therapy. If Coombs-positive hemolytic anemia occurs, the cause may be methyldopa and the drug should be discontinued. Usually the anemia remits promptly. If not, corticosteroids may be given and other causes of anemia should be considered. If the hemolytic anemia is related to methyldopa, the drug should not be reinstated. When methyldopa causes Coombs positivity alone or with hemolytic anemia, the red cell is usually coated with gamma globulin of the IgG (gamma G) class only. The positive Coombs test may not revert to normal until weeks to months after methyldopa is stopped.

Should the need for transfusion arise in a patient receiving methyldopa, both a direct and an indirect Coombs test should be performed on his blood. In the absence of hemolytic anemia, usually only the direct Coombs test will be positive. A positive direct Coombs test alone will not interfere with typing or cross matching. If the indirect Coombs test is also positive, problems may arise in the major cross match and the assistance of a hematologist or transfusion expert will be needed.

Fever has occurred within first 3 weeks of therapy, occasionally with eosinophilia or abnormalities in liver function tests, such as serum alkaline phosphatase, serum transaminases (SGOT, SGPT), bilirubin, cephalin cholesterol flocculation, prothrombin time, and bromsulphalein retention. Jaundice, with or without fever, may occur, with onset usually in the first 2 to 3 months of therapy. In some patients the findings are consistent with those of cholestasis. Rarely fatal hepatic necrosis has been reported. These hepatic changes may represent hypersensitivity reactions; periodic determination of hepatic function should be done particularly during the first 6 to 12 weeks of therapy or whenever an unexplained fever occurs. If fever and abnormalities in liver function tests or jaundice appear, stop therapy with methyldopa. If caused by methyldopa, the temperature and abnormalities in liver function characteristically have reverted to normal when the drug was discontinued. Methyldopa should not be reinstated in such patients. Rarely, a reversible reduction of the white blood cell count with primary effect on granulocytes has been seen. Reversible thrombocytopenia has occurred rarely. When used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. Patients should be followed carefully to detect side reactions or unusual manifestations of drug idiosyncrasy.

**Pregnancy and Nursing:** Use of any drug in women who are or may become pregnant or intend to nurse requires that anticipated benefits be weighed against possible risks; possibility of fetal injury or injury to a nursing infant cannot be excluded. Methyldopa crosses the placental barrier, appears in cord blood, and appears in breast milk.

**Precautions:** Should be used with caution in patients with history of previous liver disease or dysfunction (see Warnings). May interfere with measurement of: urinary uric acid by the phosphotungstate method, serum creatinine by the alkaline picrate method, and SGOT by colorimetric methods. Since methyldopa causes fluorescence in urine samples at the same wavelengths as catecholamines, falsely high levels of urinary catecholamines may be reported. This will interfere with the diagnosis of pheochromocytoma. It is important to recognize this phenomenon before a patient with a possible pheochromocytoma is subjected to surgery. Methyldopa is not recommended for patients with pheochromocytoma. Urine exposed to air after voiding may darken because of breakdown of methyldopa or its metabolites.

Stop drug if involuntary choreoathetoid movements occur in patients with severe bilateral cerebrovascular disease. Patients may require reduced doses of anesthetics; hypotension occurring during anesthesia usually can be controlled with vasopressors. Hypertension has recurred after dialysis in patients on methyldopa because the drug is removed by this procedure.

**Adverse Reactions:** *Central nervous system:* Sedation, headache, asthenia or weakness, usually early and transient; dizziness, lightheadedness, symptoms of cerebrovascular insufficiency, paresthesias, parkinsonism, Bell's palsy, decreased mental acuity, involuntary choreoathetoid movements; psychic disturbances, including nightmares and reversible mild psychoses or depression. *Cardiovascular:* Bradycardia, prolonged carotid sinus hypersensitivity, aggravation of angina pectoris. Orthostatic hypotension (decrease daily dosage). Edema (and weight gain) usually relieved by use of a diuretic. (Discontinue methyldopa if edema progresses or signs of heart failure appear.) *Gastrointestinal:* Nausea, vomiting, distention, constipation, flatulence, diarrhea, colitis, mild dryness of mouth, sore or "black" tongue, pancreatitis, sialadenitis. *Hepatic:* Abnormal liver function tests, jaundice, liver disorders. *Hematologic:* Positive Coombs test, hemolytic anemia. Bone marrow depression, leukopenia, granulocytopenia, thrombocytopenia. Positive tests for antinuclear antibody, LE cells, and rheumatoid factor. *Allergic:* Drug-related fever, lupus-like syndrome, myocarditis. *Dermatologic:* Rash as in eczema or lichenoid eruption; toxic epidermal necrolysis. *Other:* Nasal stuffiness, rise in BUN, breast enlargement, gynecomastia, lactation, hyperprolactinemia, amenorrhea, impotence, decreased libido, mild arthralgia, myalgia.

**Note:** Initial adult dosage should be limited to 500 mg daily when given with antihypertensives other than thiazides. Tolerance may occur, usually between second and third months of therapy; increased dosage or adding a diuretic frequently restores effective control. Patients with impaired renal function may respond to smaller doses. Syncope in older patients may be related to increased sensitivity and advanced arteriosclerotic vascular disease; this may be avoided by lower doses.

For more detailed information, consult your MSD Representative or see Prescribing Information. Merck Sharp & Dohme, Division of Merck & Co., Inc., West Point, PA 19486

**MSD**  
**MERCK**  
**SHARP &**  
**DOHME**  
J2AM43R(716)

Continued from page 136

have lacked role models in their formal education who inquired about family psychiatric history. It is possible that textbook recommendations are overlooked or forgotten if they are not validated through the performance of attending physicians or peers. One comment about embarrassment suggested that the cultural taboo surrounding mental illness might affect some physicians' ability to conduct a comprehensive medical interview. Just as certain issues of sexuality and death have been avoided by some physicians, inquiry about mental disorders, including alcoholism, may also trigger inhibitions and a sense of personal threat, especially if physicians have had a similar disorder in themselves or in a family member. Greater psychosocial interest of physicians who take family histories was indicated by the positive relationship between family history taking and provision of psychosocial counseling.

When compared with pediatricians, the greater tendency of family physicians to take histories is noteworthy. Training or selection factors may account for this difference. The difference in history taking between younger family physicians and pediatricians may have been accentuated by the increasing availability of family practice residencies in the 1970s. Physicians aged over 40 years who are categorized as family physicians most likely did not have a family practice residency. Family practice residencies have characteristically encouraged a focus on the whole family of the identified patient. Also, they frequently have included curriculum on the diagnosis and limited management of common mental disorders in their educational programs. These findings suggest that the recent emphasis in teaching about psychosocial concerns in family medicine is affecting physician performance.

Inquiry about family history of mental disorder provides more than information about risks and stresses facing patients; it also sets the stage for open discussion of issues about which the patient may be reticent. Furthermore, such an inquiry can provide comfort to affected families and individuals when their physicians demonstrate acceptance of mental disorders as warranting their routine consideration.

Findings from the study suggest a need to make a more concerted effort to teach the importance of

family history of mental disorders in comprehensive care.

#### References

1. Jakimow-Venulet B: Hereditary factors in the pathogenesis of affective illness. *Br J Psychiatry* 138:450, 1981
2. Schulsinger H: A ten-year followup of children of schizophrenic mothers. Clinical assessment. *Acta Psychiatr Scand* 53:371, 1976
3. Wheeler EO, White PD, Reid EW, et al: Familial inci-

dence of neurocirculatory asthenia (anxiety neurosis, effort syndrome). *J Clin Invest* 27:562, 1948

4. Hoaken PCS, Schnurr R: Genetic factors in obsessive-compulsive neurosis? A case of discordant monozygotic twins. *Can J Psychiatry* 25:167, 1980

5. McKnew DH, Cytryn L, Efron AM, et al: Offspring of patients with affective disorders. *Br J Psychiatry* 134:148, 1978

6. Conners CK, Himmelhock J, Goyette CH, et al: Children of parents with affective illness. *J Am Acad Child Psychiatry* 14:600, 1979

7. Nielsen AC III, Williams TA: Depression in ambulatory medical patients. Prevalence by self-report questionnaire and recognition by nonpsychiatric physicians. *Arch Gen Psychiatry* 37:999, 1980

# Gynecomastia Associated With Theophylline

Kenneth R. Dardick, MD  
Storrs, Connecticut

Gynecomastia is not rare; it is reported to occur in 60 to 70 percent of normal boys during puberty and 30 percent of asymptomatic adult men, with increasing frequency as men become older. Carlson's recent review<sup>1</sup> of the subject also lists many other pathological mechanisms that may cause gynecomastia (hypogonadism, neoplasms, refeeding after starvation, cirrhosis, hyperthyroidism, breast cancer). The condition may also be induced by various drugs.

When drug related, gynecomastia usually develops suddenly after the initiation of therapy and often abates when the drug is discontinued. This

report will describe a patient who developed gynecomastia while taking a drug not previously known to cause this problem—theophylline.

## Case Report

A 61-year-old man with asthma of many years' duration was given theophylline (Theo-Dur) for the first time in 200-mg time-release tablets, which were taken every 8 to 12 hours. Pharmacy records indicate that the prescription for 100 tablets was refilled about once a month for six months.

The patient developed unilateral gynecomastia one to two months after starting therapy. He was continued on the drug for four months, as the theophylline was not considered to cause the gyn-

From the Department of Medicine, School of Medicine, University of Connecticut, Farmington, Connecticut. Requests for reprints should be addressed to Dr. Kenneth R. Dardick, Mansfield Professional Park, Storrs, CT 06268.